MyAverix Finance MyAverix Finance

GSE

INTRAVENOUS INFUSIONS LIMITED (IIL)

INTRAVENOUS INFUSIONS LIMITED (IIL) is listed on GSE. As of 2026-05-21, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-21

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for IIL

P/E ratio
18.00

INTRAVENOUS INFUSIONS LIMITED (IIL) — FAQ

What is IIL's P/E ratio?

The price-to-earnings (P/E) ratio for INTRAVENOUS INFUSIONS LIMITED (IIL) is 18.00 (data as of 2026-05-21).

Does INTRAVENOUS INFUSIONS LIMITED pay a dividend?

Dividend yield is not available in the current snapshot for INTRAVENOUS INFUSIONS LIMITED (IIL). Check the MyAverix Finance app for the latest dividend data.

What exchange is IIL listed on?

IIL is listed on GSE.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play